NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Telehealth Intervention for Symptom Management and Adherence to Adjuvant Endocrine Therapy

Not Yet RecruitingNA

Sponsor: Massachusetts General Hospital

Conditions: Hormone Receptor Positive Breast Cancer

Interventions: STRIDE, Usual Care

Countries: United States

The goal of this study is to demonstrate the efficacy of an evidence-based, small-group, telehealth intervention ('STRIDE') for improving patients' ability to cope with side effects from adjuvant endocrine therapy (AET) and adhere to AET medication regimens for patients with hormone-sensitive breast cancer.

Eligibility overview

Sex: FEMALE

Age: 21 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Female ≥ 21 years old
* Diagnosis of early-stage (0-IIIb), hormone receptor positive (ER+/PR+) breast cancer
* Completed primary treatment (surgery, chemotherapy, and/or radiation)
* Within 3 to 12 months of starting oral adjuvant endocrine therapy (AET)
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
* Ability to read and respond in English or Spanish
* Distress about AET ≥ 4 on a 0-10 scale

Exclusion Criteria:

* Cognitive impairment, uncontrolled psychosis, or serious mental illness prohibiting participation in the study as per the judgment of the treating oncologist
* Enrolled in a clinical trial for AET

Locations (2)

Tampa, Florida, United States
Boston, Massachusetts, United States